Bolt Biotherapeutics vs Marker Therapeutics
BOLT and MRKR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BOLT and MRKR compare
Marker Therapeutics is the larger company, worth 1.2 times as much as Bolt Biotherapeutics ($14.5M against $11.7M).
Bolt Biotherapeutics scores higher on the StockData Score (11 against 6 for Marker Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BOLT | MRKR |
|---|---|---|
| Size and price | ||
| Market cap | $11.7M | $14.5M |
| Share price | $6.08 | $0.870 |
| Change, 1 year | 29.6% | −7.8% |
| Change, 5 years | −96.5% | −93.3% |
| Beta (5Y) | 0.63 | 1.27 |
| Employees | 23 | 5 |
| StockData Score | ||
| Total score | 11 (better) | 6 |
| Valuation score | 3 (better) | 1 |
| Growth score | 2 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.5× | – |
| P/B | 0.9× (better) | 1.2× |
| Fair value | $8.70 | – |
| Margin of safety | 30.1% | – |
| Growth | ||
| Revenue growth (TTM) | 12.8% | – |
| Revenue growth, 5Y average | 102% (better) | 48.0% |
| Profitability | ||
| Operating margin | −655% | – |
| Net margin | −611% | – |
| Return on equity | −112% | −76.9% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 2.61 | 6.03 (better) |
| Altman Z-score | −18.28 (better) | −42.38 |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −0.26% | – |
| Shareholder yield | −0.26% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 31.0% | 23.8% |
| Held by insiders | 12.2% | 31.9% |
| Insider net buying, 12 months | $196K | – |
| Short interest, % of float | 2.8% | 1.6% |
Go deeper
- BOLT stock overview
- BOLT income statement
- BOLT valuation and score
- MRKR stock overview
- MRKR income statement
- MRKR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.